Intranasal ipratropium: A new treatment for perennial rhinitis

Publisher Website
Google Scholar
Abstract
Eighty MS of the topically active parasympatholytic ipratropium [IT] were applied intranasally 4 .times./day to 20 adult patients with perennial rhinitis and severe watery rhinorrhoea in a double-blind placebo controlled cross-over trial. There was a significant reduction in nasal hypersecretion during IT treatment. Patients [14] preferred the IP period, 3 the placebo period and 3 had no preference. There were no adverse systemic or local effects. IT was effective also in patients resistant to glucocorticoids, sodium cromoglycate and antihistaminics. As the drug works immediately it can also be used before exposure to known provocating factors. Continuous use of this new medication is apparently of value in the management of severe rhinorrhoea in patients with perennial rhinitis, and that the occasional use is helpful in subjects with infrequent attacks of nasal hypersecretion.

This publication has 4 references indexed in Scilit: